ATE223385T1 - 1,2,3-triazole und imidazol derivate und ihre verwendung als antitumormittel - Google Patents

1,2,3-triazole und imidazol derivate und ihre verwendung als antitumormittel

Info

Publication number
ATE223385T1
ATE223385T1 AT93915246T AT93915246T ATE223385T1 AT E223385 T1 ATE223385 T1 AT E223385T1 AT 93915246 T AT93915246 T AT 93915246T AT 93915246 T AT93915246 T AT 93915246T AT E223385 T1 ATE223385 T1 AT E223385T1
Authority
AT
Austria
Prior art keywords
compounds
metastasis
inhibit
signal transduction
solid tumors
Prior art date
Application number
AT93915246T
Other languages
English (en)
Inventor
Elise C Kohn
Lance A Liotta
Christian C Felder
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE223385T1 publication Critical patent/ATE223385T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT93915246T 1992-06-08 1993-06-08 1,2,3-triazole und imidazol derivate und ihre verwendung als antitumormittel ATE223385T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89489192A 1992-06-08 1992-06-08
US94400992A 1992-09-11 1992-09-11
US07/985,402 US5359078A (en) 1989-05-19 1992-12-04 Signal transduction inhibitor compounds
PCT/US1993/005438 WO1993025536A1 (en) 1992-06-08 1993-06-08 1,2,3-triazole and imidazole compounds and their antitumor use

Publications (1)

Publication Number Publication Date
ATE223385T1 true ATE223385T1 (de) 2002-09-15

Family

ID=27420555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93915246T ATE223385T1 (de) 1992-06-08 1993-06-08 1,2,3-triazole und imidazol derivate und ihre verwendung als antitumormittel

Country Status (8)

Country Link
US (3) US5359078A (de)
EP (1) EP0644880B1 (de)
JP (1) JP3811726B2 (de)
AT (1) ATE223385T1 (de)
AU (1) AU678767B2 (de)
CA (1) CA2136356C (de)
DE (1) DE69332269D1 (de)
WO (1) WO1993025536A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132315A (en) 1989-05-19 1992-07-21 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic application of an anti-invasive compound
US5744492A (en) * 1993-09-17 1998-04-28 United States Of America Method for inhibiting angiogenesis
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
US6790936B1 (en) 1994-03-14 2004-09-14 The United States Of America As Represented By The Department Of Health And Human Services CAI resistance proteins and uses thereof
US5652223A (en) * 1994-03-14 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA encoding CAI resistance proteins and uses thereof
US6057346A (en) * 1994-12-12 2000-05-02 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of retroviral LTR promoters by calcium response modifiers
US6358915B1 (en) * 1995-03-07 2002-03-19 George Washington University Methods for inhibiting metastasis
US6509316B2 (en) 1995-03-07 2003-01-21 George Washington University Pharmaceutical compositions, methods, and kits for treatment and diagnosis of lung cancer
US6288039B1 (en) 1995-03-07 2001-09-11 George Washington University Pharmaceutical compositions methods and kits for treatment and diagnosis of breast cancer
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
US5696092A (en) * 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
WO1997003668A1 (en) * 1995-07-21 1997-02-06 Constantia Gruppe Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
JP4056589B2 (ja) * 1996-07-19 2008-03-05 武田薬品工業株式会社 複素環化合物、その製造法および用途
KR20000065227A (ko) * 1996-07-19 2000-11-06 다께다 구니오 복소환 화합물, 그의 제조방법 및 용도
DE69722220T2 (de) * 1996-08-09 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield 4-substituierte beta-carboline als immunomodulatoren
US6238881B1 (en) * 1996-11-06 2001-05-29 Onyx Pharmaceuticals, Inc. Nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase
US6352833B1 (en) * 1999-04-28 2002-03-05 Michael E. Mendelsohn Methods for discovery of vasoactive compounds for the nitric oxide-cyclic GMP signal pathway
JP4114029B2 (ja) * 1999-07-16 2008-07-09 株式会社セガ 画像処理装置、画像処理方法及び記録媒体
EP1466898A4 (de) 2001-12-27 2005-12-07 Daiichi Seiyaku Co Inhibitoren der produktion/sezernierung von beta-amyloiden proteinen
AU2003293141A1 (en) * 2002-11-25 2004-06-18 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
WO2004048546A2 (en) * 2002-11-25 2004-06-10 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
TW200505913A (en) * 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
JP4523914B2 (ja) 2003-06-30 2010-08-11 第一三共株式会社 複素環メチルスルホン誘導体
US20050272043A1 (en) * 2003-07-24 2005-12-08 Roth Richard B Methods for identifying risk of breast cancer and treatments thereof
US7517890B2 (en) 2003-11-20 2009-04-14 Children's Hospital Medical Center GTPase inhibitors and methods of use
US20090258344A1 (en) * 2004-05-27 2009-10-15 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
EP1920048A4 (de) 2005-07-29 2009-12-09 Childrens Hosp Medical Center Gtase-hemmer und verwendungsverfahren und kristallstruktur von rac-1-gtase
CN101164538B (zh) 2006-10-16 2011-12-14 中国医学科学院基础医学研究所 羧胺三唑类化合物及其盐在制备治疗疼痛性疾病和/或炎症性疾病的药物中的应用
US8912223B2 (en) 2009-09-04 2014-12-16 Tactical Therapeutics Inc Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations
US8377973B2 (en) 2009-09-04 2013-02-19 Tactical Therapeutics Inc Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
EP3565806B1 (de) * 2017-01-06 2022-03-02 Rivus Pharmaceuticals, Inc. Neue phenylderivate
EP4013402B1 (de) 2019-08-16 2024-11-06 Children's Hospital Medical Center Cdc-42-inhibitoren zur verwendung bei der behandlung von altersverbundener depression, sarkopenie oder gebrechlichkeit
CN118766907A (zh) * 2023-04-04 2024-10-15 广东银珠医药科技有限公司 羧胺三唑在制备治疗肿瘤骨转移的药物中的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2927988A1 (de) * 1979-07-11 1981-02-05 Thomae Gmbh Dr K Neue 8-phenyl-purine, deren herstellung und deren verwendung als arzneimittel
JPS5962593A (ja) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３―置換―５，７―ジクロルトリアゾロピリミジン誘導体
IE56381B1 (en) * 1982-12-20 1991-07-17 Merck & Co Inc 5-(amino or substituted amino)imidazoles
US4659720A (en) * 1982-12-20 1987-04-21 Merck & Co., Inc. 5-amino or substituted amino imidazoles useful to treat coccidiosis
FI834666A7 (fi) * 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
US4590201A (en) * 1984-02-02 1986-05-20 Merck & Co., Inc. 5-amino or substituted amino 1,2,3-triazoles
DE3578499D1 (de) * 1984-02-02 1990-08-09 Merck & Co Inc 5-(amino oder substituiertes amino)-1,2,3-triazole.
US4816469A (en) * 1984-02-02 1989-03-28 Merck & Co., Inc. 5-Amino or substituted amino 1,2,3-triazoles
US4752611A (en) * 1985-11-29 1988-06-21 Merck & Co., Inc. Anticoccidial 1,2,3-trazole compounds
EP0229011A1 (de) * 1986-01-06 1987-07-15 Ciba-Geigy Ag Trisubstituierte Triazole
EP0288431B1 (de) * 1987-04-07 1992-08-19 Ciba-Geigy Ag 3H-1,2,3-Triazolo[4,5-d]pyrimidine
US4847257A (en) * 1987-08-20 1989-07-11 Merck & Co., Inc. 5-Amino or substituted amino 1,2,3,-triazoles useful as antiproliferative agents
US4923885A (en) * 1988-08-19 1990-05-08 Merck & Co., Inc. 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents
US5132315A (en) * 1989-05-19 1992-07-21 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic application of an anti-invasive compound

Also Published As

Publication number Publication date
AU678767B2 (en) 1997-06-12
US5482954A (en) 1996-01-09
WO1993025536A1 (en) 1993-12-23
EP0644880B1 (de) 2002-09-04
JP3811726B2 (ja) 2006-08-23
CA2136356A1 (en) 1993-12-23
AU4530193A (en) 1994-01-04
JPH07508000A (ja) 1995-09-07
EP0644880A1 (de) 1995-03-29
DE69332269D1 (de) 2002-10-10
CA2136356C (en) 2006-06-06
US5705514A (en) 1998-01-06
US5359078A (en) 1994-10-25

Similar Documents

Publication Publication Date Title
ATE223385T1 (de) 1,2,3-triazole und imidazol derivate und ihre verwendung als antitumormittel
EA200000274A2 (ru) Способы получения и промежуточные соединения для получения противораковых соединений
EA200200768A1 (ru) Соединения индазола, фармацевтические композиции и методы модуляции или ингибирования клеточной пролиферации
NZ311403A (en) Imidazole compounds and pharmaceuticals
MX9803851A (es) Compuestos macrociclicos novedosos como inhibidores de metaloproteasas.
NZ312840A (en) Ketoheterocyclic inhibitors of factor Xa
EA200600123A1 (ru) 3,5-дизамещённые индазольные соединения, фармацевтические композиции и способы опосредования или ингибирования клеточной пролиферации
BG104996A (en) Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
RU94046364A (ru) Замещенные гетероциклы, способ их получения, фармокомпозиция, способ лечения
ATE283271T1 (de) Porphyrin derivate, ihre verwendung in der photodynamischen therapie und diese enthaltende medizinische geräte
PT920312E (pt) Derivados de adamantilo indutores de apoptose e sua utilizacao como agentes anticancerigenos
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
MXPA03006749A (es) Proceso para la sintesis de compuestos de urea sustituidos con heteroarilo, utiles como agentes antiinflamatorios.
MX9705313A (es) Benzazepinas triciclicas antagonistas de la vasopresina.
UA48939C2 (uk) Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки
BR9808010A (pt) Compostos de 2-alquil-19-nor-vitamina d
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
ATE199552T1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
GB9323165D0 (en) Compounds
BG102003A (en) PYRIDO/2,3-d/PYRIMIDINES FOR THE INHIBITION OF CELLULAR PROLIFERATION CAUSED BY PROTEINTHYROSIKINASE
EA200200120A1 (ru) Соединения индазола, фармацевтические препараты для ингибирования протеинкиназ и способы их применения
TR200003472T2 (tr) Yeni 2-alkil ikameli imidazol bileşikler
MX9705415A (es) Antagonsitas de vasopresina triciclicos de benzazepina.
FR2434163A1 (fr) Nouveaux 1-(2-aryl-4,5-disubstitue-1,3-dioxolane-2-ylmethyl)-1h-imidazoles et 1h-1,2,4-triazoles, leur procede de preparation et application en phytopharmacie pour combattre des champignons

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties